Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3022573 | 0.81 | CDK8 (0.32) | ALDH1A1POLBHPGDKDM4EL3MBTL1 | |
| SCHEMBL3016189 | 0.79 | TDP1 (0.35) | TDP1ALDH1A1TSHRPOLBHPGD | |
| SCHEMBL4996473 | 0.70 | SMN1; SMN2 (0.33) | TDP1ALDH1A1TSHRHPGDNPSR1 | |
| SCHEMBL2437573 | 0.68 | AR (0.35) | TDP1ALDH1A1TSHRNPSR1 | |
| SCHEMBL4815221 | 0.66 | TSHR (0.51) | TDP1ALDH1A1TSHRPOLBHPGD | |
| SCHEMBL5004221 | 0.66 | SMN1; SMN2 (0.40) | TDP1ALDH1A1TSHRPOLBHPGD | |
| SCHEMBL5513040 | 0.65 | CA2 (0.41) | TDP1ALDH1A1TSHRPOLBHPGD | |
| SCHEMBL6515361 | 0.64 | TP53 (0.37) | TDP1ALDH1A1TSHRPKM | |
| SCHEMBL27946142 | 0.64 | HPGD (0.47) | TDP1ALDH1A1TSHRPOLBHPGD | |
| SCHEMBL7077212 | 0.63 | ALDH1A1 (0.36) | TDP1ALDH1A1TSHRNPSR1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426443-B2 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2013-04-23 | — | — | US | disclosed |
| US-20120316196-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | GLAXO GROUP LIMITED (GB) | 2012-12-13 | — | — | US | disclosed |
| US-8278328-B2 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| US-20100204272-A1 | Compounds which have activity at M1 receptor and their uses in medicine | Glaxo Group Limited a corporation | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204272-A1 | Compounds which have activity at M1 receptor and their uses in medicine | CHRM1, CHRM2, CHRM5 | TDP1 2927/4885ALDH1A1 1041/4885TSHR 263/4885 |
| US-20120316196-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | CHRM1, CHRM2, CHRM5 | TDP1 2927/4885ALDH1A1 1041/4885TSHR 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.